Musculoskeletal disorders

We will:

1. investigate molecular, cellular and structural determinants of bone loss and fracture in primary and secondary osteoporosis and to establish how these are affected by pharmacological interventions used to reduce fracture risk;

 

2. extend identification of pathogenetic factors in osteoporosis to optimise development of new treatments in inflammatory arthritis

 

3. work with the Cambridge Centre for Medical Materials to develop and evaluate new biomaterials for use in orthopaedic procedures.